Gemcitabine in Treating Children With Refractory Solid Tumors

PHASE1CompletedINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

August 31, 1996

Primary Completion Date

September 30, 2002

Conditions
Unspecified Childhood Solid Tumor, Protocol Specific
Interventions
DRUG

gemcitabine hydrochloride

Trial Locations (23)

6001

Princess Margaret Hospital for Children, Perth

10016

NYU School of Medicine's Kaplan Comprehensive Cancer Center, New York

10021

Memorial Sloan-Kettering Cancer Center, New York

10032

Herbert Irving Comprehensive Cancer Center, New York

15213

Children's Hospital of Pittsburgh, Pittsburgh

19104

Children's Hospital of Philadelphia, Philadelphia

55455

University of Minnesota Cancer Center, Minneapolis

55905

Mayo Clinic Cancer Center, Rochester

64108

Children's Mercy Hospital, Kansas City

84112

Huntsman Cancer Institute, Salt Lake City

92868

Children's Hospital of Orange County, Orange

98105

Children's Hospital and Regional Medical Center - Seattle, Seattle

90027-0700

Children's Hospital Los Angeles, Los Angeles

90095-1781

Jonsson Comprehensive Cancer Center, UCLA, Los Angeles

91010-3000

Cancer Center and Beckman Research Institute, City of Hope, Los Angeles

94143-0128

UCSF Cancer Center and Cancer Research Institute, San Francisco

20010-2970

Children's National Medical Center, Washington D.C.

46202-5289

Indiana University Cancer Center, Indianapolis

48109-0752

University of Michigan Comprehensive Cancer Center, Ann Arbor

45229-3039

Children's Hospital Medical Center - Cincinnati, Cincinnati

37232-6838

Vanderbilt-Ingram Cancer Center, Nashville

77030-4009

University of Texas - MD Anderson Cancer Center, Houston

53792-6164

University of Wisconsin Comprehensive Cancer Center, Madison

All Listed Sponsors
lead

National Cancer Institute (NCI)

NIH

NCT00005577 - Gemcitabine in Treating Children With Refractory Solid Tumors | Biotech Hunter | Biotech Hunter